Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $40.75 Average PT from Brokerages

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has been assigned a consensus recommendation of “Hold” from the five analysts that are currently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $40.75.

A number of brokerages have recently issued reports on COLL. Piper Sandler cut shares of Collegium Pharmaceutical from an “overweight” rating to a “neutral” rating and set a $39.00 price objective for the company. in a report on Friday, May 10th. Needham & Company LLC cut shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Friday, May 10th. StockNews.com lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, May 1st. Finally, Jefferies Financial Group raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and increased their price objective for the stock from $41.00 to $44.00 in a research note on Friday, June 7th.

Collegium Pharmaceutical Trading Up 1.3 %

Shares of Collegium Pharmaceutical stock opened at $32.62 on Thursday. The stock has a market capitalization of $1.07 billion, a PE ratio of 13.59 and a beta of 0.96. Collegium Pharmaceutical has a 52 week low of $20.83 and a 52 week high of $40.95. The stock has a 50 day moving average price of $33.78 and a two-hundred day moving average price of $34.40. The company has a debt-to-equity ratio of 1.98, a quick ratio of 1.14 and a current ratio of 1.21.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, May 9th. The specialty pharmaceutical company reported $1.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.04). The firm had revenue of $144.92 million during the quarter, compared to the consensus estimate of $147.04 million. Collegium Pharmaceutical had a return on equity of 104.98% and a net margin of 16.46%. As a group, equities analysts anticipate that Collegium Pharmaceutical will post 5.57 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Colleen Tupper sold 19,710 shares of Collegium Pharmaceutical stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $34.21, for a total value of $674,279.10. Following the sale, the chief financial officer now owns 130,845 shares of the company’s stock, valued at approximately $4,476,207.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 19,710 shares of the company’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $34.21, for a total value of $674,279.10. Following the transaction, the chief financial officer now directly owns 130,845 shares in the company, valued at approximately $4,476,207.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Scott Dreyer sold 56,807 shares of the firm’s stock in a transaction on Friday, May 24th. The shares were sold at an average price of $33.98, for a total transaction of $1,930,301.86. Following the sale, the executive vice president now owns 105,902 shares in the company, valued at approximately $3,598,549.96. The disclosure for this sale can be found here. In the last ninety days, insiders sold 105,502 shares of company stock valued at $3,540,796. Corporate insiders own 3.98% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

Several institutional investors have recently added to or reduced their stakes in the business. Pacer Advisors Inc. lifted its stake in Collegium Pharmaceutical by 68.4% during the 4th quarter. Pacer Advisors Inc. now owns 2,174,718 shares of the specialty pharmaceutical company’s stock valued at $66,938,000 after acquiring an additional 883,380 shares during the period. BNP Paribas Financial Markets lifted its position in Collegium Pharmaceutical by 119.6% during the fourth quarter. BNP Paribas Financial Markets now owns 146,543 shares of the specialty pharmaceutical company’s stock valued at $4,511,000 after purchasing an additional 79,823 shares during the period. SummerHaven Investment Management LLC boosted its holdings in Collegium Pharmaceutical by 1.1% in the fourth quarter. SummerHaven Investment Management LLC now owns 34,034 shares of the specialty pharmaceutical company’s stock worth $1,048,000 after purchasing an additional 368 shares during the last quarter. Johnson Investment Counsel Inc. bought a new stake in Collegium Pharmaceutical in the 4th quarter worth approximately $257,000. Finally, Natixis Advisors L.P. raised its stake in Collegium Pharmaceutical by 152.9% during the 3rd quarter. Natixis Advisors L.P. now owns 54,359 shares of the specialty pharmaceutical company’s stock valued at $1,215,000 after buying an additional 32,865 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.